IP Library › Granted Patent US 12,616,726
Granted Patent B2
US 12,616,726 · App. 18/618,941 · Granted May 5, 2026

Probiotic supplement for metabolic health

Inventors: Nanna Ny Kristensen (Bagsvaerd, DK); Delphine Marie Anne Saulnier (Berlin, DE); Jeffrey Schultchen (Berlin, DE); Alexandra Mattern (Berlin, DE); Teis Jensen (Bagsvaerd, DK); Benjamin Anderschou Holbech Jensen (Québec, CA)
Assignee: Novozymes A/S
A61K35/747A23L33/135A23L33/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,616,726
App. No.
18/618,941
Granted
May 5, 2026
Kind
B2
Abstract

The application discloses Lactobacillus strains having a beneficial effect on the metabolic health on a mammalian subject. Further disclosed is compositions comprising such strains and the use thereof for improving the metabolic health or for lowering the blood glucose level in a mammalian subject.

Claims (13)

1 . A method of alleviating prediabetes or lowering the blood glucose level of an individual in need thereof, the method comprising administering to the individual Lactobacillus strain DSM 32851.

2 . The method of claim 1 , wherein the method results in improving or alleviating one or more prediabetes symptoms in the individual selected from insulin resistance, high-blood glucose, low-grade inflammation and gut barrier function.

3 . The method of claim 1 , wherein the individual is a human.

4 . The method of claim 1 , wherein the individual is a mammalian subject.

5 . The method of claim 1 , wherein the strain is in freeze-dried form.

6 . The method of claim 1 , wherein the strain is in spray-dried form.

7 . The method of claim 1 , wherein the stain is administered as composition comprising 10 6 -10 14 colony forming units (CFU) of total Lactobacillus strain per gram of the composition.

8 . The method of claim 1 , wherein the stain is administered as composition comprising 10 7 -10 13 colony forming units (CFU) of total Lactobacillus strain per gram of the composition.

9 . The method of claim 1 , wherein the stain is administered as composition comprising 10 8 -10 12 colony forming units (CFU) of total Lactobacillus strain per gram of the composition.

10 . The method of claim 1 , wherein the strain survives in the gastrointestinal (GI) tract.

11 . The method of claim 1 , comprising administering strain Lactobacillus DSM 32851 together with one or more Lactobacillus strains DSM 17648, DSM 32910, DSM 32911 and DSM 32853.

12 . The method of claim 1 , comprising administering strain Lactobacillus DSM 32851 together with Lactobacillus DSM 32910.

13 . The method of claim 1 , wherein the strain is administered orally.

Priority Claims (1)
EP 18202187 · Oct 24, 2018 · regional
Continuity (2)
Continuation 17287719
Related Publication 20240238354A1 · Jul 18, 2024
References Cited (37)
US 7846711B2 · Boettner et al. · 2010 [cited by applicant]
US 7901926B2 · Yu et al. · 2011 [cited by applicant]
US 8298526B2 · Leu et al. · 2012 [cited by applicant]
US 9265719B2 · Castiel · 2016 [cited by examiner]
US 11963986B2 · Kristensen · 2024 [cited by examiner]
US 20070148149A1 · Boettner et al. · 2007 [cited by applicant]
US 20090208469A1 · Alenfall et al. · 2009 [cited by applicant]
US 20110300117A1 · Leu et al. · 2011 [cited by applicant]
US 20120020942A1 · Bottner et al. · 2012 [cited by applicant]
US 20140079676A1 · Olmstead · 2014 [cited by applicant]
US 20140147427A1 · Arya et al. · 2014 [cited by applicant]
US 20150196608A1 · Chen et al. · 2015 [cited by applicant]
US 20150250835A1 · Huang et al. · 2015 [cited by applicant]
US 20150374764A1 · Robins et al. · 2015 [cited by applicant]
US 20160279181A1 · Hoshiko · 2016 [cited by applicant]
CN 101325960A · 2008 [cited by applicant]
CN 101384700A · 2009 [cited by applicant]
CN 102935092A · 2013 [cited by applicant]
CN 104968780A · 2015 [cited by applicant]
CN 107375344 · 2017 [cited by applicant]
EP 2543379A1 · 2010 [cited by applicant]
GB 201400407 · 2014 [cited by applicant]
KR 101864347 · 2018 [cited by applicant]
WO 2007125558A1 · 2007 [cited by applicant]
WO 2017097984A1 · 2017 [cited by applicant]
Peijun Tian et al. “Antidiabetic (type 2) effects of Lactobacillus G15 and Q14 in rats through regulation of intestinal permeability and microbiota”. Food and Function. 2016, 7, pp. 3789-3797. [cited by examiner]
Skovso. “Modeling type 2 diabetes in rats using high fat diet and streptozotocin”. J Diabetes Invest 2014, 5, pp. 349-358. [cited by examiner]
Genmont Biotech Inc., 2013, abstract of CN102935092. [cited by applicant]
Hill, 2014, Nature reviews, 11, 506-514. [cited by applicant]
Holz, 2015, Probiotics and Antimicro. proteins, 7(2). [cited by applicant]
Maragkoudakis, 2006, International dairy journal, 16(3), 189-199. [cited by applicant]
Maragkoudakis et al., International Journal of Food Microbiology, 141, S91-S97, 2010. [cited by applicant]
Tian et al., Food and Function, 7, 3789-3797, 2016. [cited by applicant]
Wang et al., Acta Microbiologica Sinica, 58(7)—Incl EnAb, 1287-1297, 2017. [cited by applicant]
Wei, 2015, Journal of Functional Foods, 18, 473-486. [cited by applicant]
Genome and Company et al., Jun. 5, 2018; abstract of KR101864347. [cited by applicant]
Nanchang Univ., Nov. 24, 2017; abstract of CN107375344. [cited by applicant]